Markers of bone turnover after 12 months of exercise in patients with chronic kidney disease 3–5 : a post-hoc analysis of RENEXC – a randomized controlled trial
Background: Bone and mineral disorders are common in patients with chronic kidney disease (CKD), leading to poor quality of life, high fracture risk, and increased morbidity and cardiovascular mortality. Parathyroid hormone (PTH) and bone-specific alkaline phosphatase (bALP) are frequently used to assess bone turnover, but markers such as procollagen type I N-terminal propeptide (intact PINP) and
